Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ZS Pharma

- PMLiVE

Pfizer rumoured to be after AstraZeneca

Is this the return of the pharma mega-merger?

- PMLiVE

AZ teams up with UK’s MRC for discovery centre

Public-private facility will be based at the pharma company's Cambridge R&D site

- PMLiVE

AstraZeneca launches delivery service for Nexium

Expands its US direct-to-patient programme

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

- PMLiVE

Boehringer/Lilly’s empagliflozin among CHMP recommendations

If approved it will be marketed as Jardiance

AstraZeneca to develop mHealth cardiovascular services

Willwork with Vodafone in a new global partnership

- PMLiVE

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

- PMLiVE

Alderley Park ‘will remain flagship bioscience location’

Manchester Science Parks takes over former AstraZeneca site

- PMLiVE

AZ launches combination diabetes drug in UK

Xigduo combines Forxiga and metformin

- PMLiVE

AstraZeneca loses comms head

Neil McCrae to join UK’s Royal Mail

Interview: Christopher Boulton, AstraZeneca

AstraZeneca’s director of UK marketing and medicines access on the company's increased focused on diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links